Abstract
With the advancement of technology for genome analysis using next-generation sequencers, comprehensive knowledge of large-scale cancer genomes has been cataloged. Using these data, a clinical sequencing for selection of therapeutic approaches based on comprehensive genomic profiling of individual cancers is becoming a driving force in precision oncology. However, the current clinical sequencing for precision oncology is a developing diagnostic tool that rarely reaches a therapeutic drug. To develop the next-generation individualized treatment for cancer, it is necessary to develop novel biomarkers, therapeutic reagents, and methods for responding to drug resistance and recurrence of cancers through deeply understanding molecular subtype and spatiotemporal heterogeneity of cancers as well as molecular mechanisms of carcinogenesis based on various omics data. Ii is also necessary to utilize liquid biopsy, which can provide information of cancer genome in non-invasive and real-time manners, and artificial intelligence technology, which is useful to reduce costs for analysis/annotation/interpretation of clinical sequence data and standardize the selection of therapeutic reagents.
